The definitive guide to gene editing.
★
Menu
Home Learn News Ask the Atlas
Explore Technologies Diseases Treatments Clinical Trials Companies Scientists Genes Research Institutions
Beyond medicine Agriculture Ethics Investing World map
Learn & Tools Start here Glossary A–Z Compare technologies Timeline Lists & Rankings AI Agents ★ Saved API
About About us Methodology Data Sources Editorial Policy Contact Disclaimers

🧭 Guided View
New to genetics? We explain every term as you browse, in plain English. Same pages, with the help built in.

⚡ Expert View
You already know the biology. Just the content — clean and compact, no extra explanations. This is the default view.

Interface language
Light mode

Private company · Cambridge, Massachusetts

Arbor Biotechnologies

Co-founded by Feng Zhang and David Scott to discover new editing enzymes from nature at scale.

Phase I Novel editors

In one paragraph

Arbor mines genetic data from microbes for editing proteins nobody has characterised yet, then engineers the promising ones into therapies. Its lead programme targets a rare metabolic disease that causes kidney failure in children.

Arbor Biotechnologies was founded in 2016 by Feng Zhang, David Scott, David Walt and Winston Yan. It combines computational discovery of novel CRISPR-associated proteins with protein engineering. Its lead clinical programme, ABO-101, targets primary hyperoxaluria type 1.

Sources

Not investment advice This profile is educational information compiled from public disclosures. It is not a recommendation to buy, sell or hold any security, and it is not a view on the company's prospects. Biotechnology is highly speculative and most clinical programmes fail. Full disclaimers →
Written by The CRISPR Atlas editorial team Last updated Aug 25, 2026

Connected in the Atlas

Every entry on this site is linked to the others it relates to. These connections are part of the record, not a search result.

Technologies

CRISPR-Cas9

Scientists

Feng Zhang